Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Non Muscle Invasive Bladder Cancer (NMIBC) - Pipeline Insights, 2015 - A DDelveInsight, the leading market research and consulting company has added a new report “NMIBC - Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline insight.
By: DelveInsight Business Research · 20+ pipeline drugs with 18+ companies actively involved in drug development. There are 3 drugs in phase III, 6 in phase II, 9 in phase I and 4 in pre-clinical. · Spectrum Pharmaceuticals developing a lead productApaziquonewhichis in Phase III. · R&D activities and technologies used along with the pipeline molecules in development. · Therapeutic assessments by molecule types, route of administration, monotherapy and combination products. · Information related to collaborations, in-licensing and out-licensing deals. DelveInsights, NMIBC - Pipeline Insights, 2015 report provides the in-depth analysis of NMIBCLandscape across the globe. Therefore the report on NMIBC - Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License. For more information on Pipeline Insight Reports, email at info@delveInsight.com Keywords DelveInsight, Indication, Collaborations, Licensing Contact Us: DelveInsight Business Research New Delhi-110075, India Phone: +91-11-45689769, +91 9650213330 Website: http://delveinsight.com About Us DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; End
|
|